The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
ApexOnco Front Page
Recent articles
GEN1286 looks dead, though MCLA-129 continues for now.
JP Morgan approaches.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Mocertatug rezetecan is starting its first western pivotal trials.
